In the BioHarmony Drug Report Database

"Preview" Icon

Verapamil

Calan, Calan Sr, Covera-hs, Isoptin, Verapamil, Verelan, Verelan Pm (verapamil) is a small molecule pharmaceutical. Verapamil was first approved as Calan on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1C and voltage-dependent L-type calcium channel subunit alpha-1S. In addition, it is known to target sodium leak channel non-selective protein, potassium voltage-gated channel subfamily A member 10, Voltage-dependent L-type calcium channel subunit alpha-1F, two pore calcium channel protein 2, G protein-activated inward rectifier potassium channel 2, cytochrome P450 3A4, voltage-dependent L-type calcium channel subunit alpha-1D, two pore calcium channel protein 1, equilibrative nucleoside transporter 4, potassium voltage-gated channel subfamily A member 7, and potassium voltage-gated channel subfamily C member 2.

 

Trade Name

 

Calan, Calan Sr, Covera-hs, Isoptin, Verapamil, Verelan, Verelan Pm
 

Common Name

 

verapamil
 

ChEMBL ID

 

CHEMBL6966
 

Indication

 

atrial fibrillation, atrial flutter, hypertension, myocardial infarction, supraventricular tachycardia, variant angina pectoris
 

Drug Class

 

Coronary vasodilators (verapamil type)

Image (chem structure or protein)

Verapamil structure rendering